Literature DB >> 8246700

Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.

A Mehrez1, A Gafni.   

Abstract

The authors respond to the contention that healthy-years equivalents (HYEs) do not fulfil claims they previously made. They refute the argument for the equivalence of the two-stage lottery and the time tradeoff and show that it fails to recognize the difference between choice problems under uncertainty versus certainty. They also dismiss the claim that HYEs assume risk neutrality with respect to healthy years of life, and show that HYEs are superior to the "general" (risk-averse) form of QALYs because HYEs employ fewer assumptions; in particular, they do not assume a specific form of the individual's utility function. The examples they used earlier are demonstrated to be conclusive, and the authors respond to arguments about the practical aspects of using HYEs vs QALYs. Finally, they take issue with the assumption that the roots of the QALY model are all attributable to utility theory.

Mesh:

Year:  1993        PMID: 8246700     DOI: 10.1177/0272989X9301300404

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  10 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

2.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

3.  Guidelines for pharmacoeconomic studies. The ways forward.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 4.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  The economic burden of coronary heart disease in the UK.

Authors:  J L Y Liu; N Maniadakis; A Gray; M Rayner
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

6.  Health profile preferences of hepatitis C patients.

Authors:  J R Treadwell; D Kearney; M Davila
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

Review 7.  Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.

Authors:  P Y Cremieux; S N Finkelstein; E R Berndt; J Crawford; M B Slavin
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

8.  Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.

Authors:  Nikolaos T Voutsas; Eleni Papageorgiou; Alexandra Tantou; Vassilis A Dimitriou; Evangelia E Tsironi; Maria Kotoula
Journal:  Int Ophthalmol       Date:  2022-04-13       Impact factor: 2.029

9.  Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

Authors:  Adrian R Levy; Shelagh Szabo; Andrew Briggs; Andreas Pleil; Alison Davie; Gergana Zlateva; Jonathan Javitt
Journal:  J Ophthalmol       Date:  2010-02-16       Impact factor: 1.909

10.  Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression.

Authors:  Maria Orlando Edelen; M Audrey Burnam; Katherine E Watkins; José J Escarce; Haiden Huskamp; Howard H Goldman; Gary Rachelefsky
Journal:  Med Decis Making       Date:  2008-08-25       Impact factor: 2.583

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.